Valeo Pharma Reports Q3 Results
Valeo Pharma press release (OTCQB:VPHIF): Q3 Revenue of $6.1M beats by $1.41M. Cash and liquidities of $27.7 million as at July 31, 2022
Valeo Pharma reports Q2 results
Valeo Pharma press release (OTCQB:VPHIF): Q2 Net loss was C$5.1M Revenue of C$4.8M (+81.1% Y/Y).
Valeo Pharma net loss of C$5.9M, revenue of C$4.2M
Valeo Pharma press release (OTCQB:VPHIF): FQ1 net loss of C$5.9M.Revenue of C$4.2M (+121.1% Y/Y).
Valeo Pharma reports Q4 results
Valeo Pharma press release (OTCQB:VPHIF): Q4 Adjusted EBITDA loss of $5.4M compared to $0.5M in Q4 2020.Revenue of $3.4M (+54.5% Y/Y) misses by $0.81M.Gross margin was $0.7M for the quarter ended Oct
Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS M
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance For Two Asthma Therapies
08:26 AM EDT, 10/05/2021 (MT Newswires) -- Valeo Pharma Inc. (VPH.CSE), which gained 7.4% yesterday, on Tuesday says it has entered into a letter of intent (LOI) with the pan-Canadian Pharmaceutical